BB Biotech AG – 2025 Annual Report Highlights
BB Biotech AG, a Swiss holding company listed on the SIX Swiss Exchange and the Frankfurt Stock Exchange, announced the publication of its 2025 annual report on 20 February 2026. The report, released through EQS‑News and other financial news outlets, details the company’s performance for the year ended 31 December 2025.
Financial Performance
- Net profit 2025: CHF 578 million, a significant increase from the CHF 76 million profit recorded in 2024.
- Quarterly contribution: The fourth quarter alone added CHF 472 million to the annual profit.
- Portfolio management: BB Biotech actively managed its holdings during the final quarter, leading to the substantial profit uplift.
Portfolio and Value Realisation
The company emphasises a strong performance and value creation across its portfolio, primarily comprising investments in drug‑development firms in the United States and Western Europe. The 2025 year is described as a period of “clear, measurable progress,” underscoring the effectiveness of BB Biotech’s investment strategy.
Corporate Context
- Industry: Biotechnology
- Sector: Health Care
- Headquarters: Kusnacht, Switzerland
- Currency: CHF
BB Biotech remains a holding vehicle that invests in biotechnology companies, maintaining its dual listing on the Swiss and German stock exchanges.
Disclosure
The information was communicated in compliance with Article 17 of Regulation (EU) No 596/2014 and Article 53 of the Swiss Code of Obligations, as provided by EQS‑News, EQS‑Cockpit, and other financial news services.
